findmyKOL
Clinical trialNCT03934840CompletedPhase 2Interventional

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

SponsorMasonic Cancer Center, University of MinnesotaEnrollment61Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone with ADT. The primary objective is to determine the percent of subjects that have no PSA or radiographic progression at 1 year. Secondary objectives will include determining the progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and cabazitaxel in combination with ADT.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Arizona

    Phoenix, Arizona, United States

  • Northwestern University

    Chicago, Illinois, United States

  • University of Chicago

    Chicago, Illinois, United States

  • Tulane University

    New Orleans, Louisiana, United States

  • Masonic Cancer Center at University of Minnesota

    Minneapolis, Minnesota, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, United States

  • Thomas Jeferson University

    Philadelphia, Pennsylvania, United States

  • Lifespan Cancer Institute

    Providence, Rhode Island, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abiraterone →Cabazitaxel →Carboplatin →Prednisone →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Oct 2019
Primary completion
19 Jun 2023
Completion
3 Apr 2025
Last update posted
26 May 2026
Registered enrollment
61
Registry id
NCT03934840
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.